Prestige Consumer Healthcare (PBH) closed at $50.62 on November 18, 2026, up 5.0% from the previous close, on volume of 580,743 shares (30-day average 568,533).
Data as of November 18, 2026.
18-Nov-2026
No headlines found.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
Globe Newswire (Thu, 5-Nov 6:00 AM ET)
Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
PRNewswire (Wed, 30-Sep 9:18 AM ET)
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
Globe Newswire (Tue, 8-Sep 5:00 PM ET)
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek Football Stress Test
PRNewswire (Tue, 1-Sep 9:18 AM ET)
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Prestige Consumer Healthcare trades on the NYSE stock market under the symbol PBH.
As of November 18, 2026, PBH stock price climbed to $50.62 with 580,743 million shares trading.
PBH has a beta of 0.76, meaning it tends to be less sensitive to market movements. PBH has a correlation of 0.07 to the broad based SPY ETF.
PBH has a market cap of $2.40 billion. This is considered a Mid Cap stock.
Last quarter Prestige Consumer Healthcare reported $336 million in Revenue and $1.13 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.06.
In the last 3 years, PBH traded as high as $90.04 and as low as $41.77.
The top ETF exchange traded funds that PBH belongs to (by Net Assets): IJR, VTI, IWM, VB, DFSV.
PBH has underperformed the market in the last year with a return of -14.2%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PBH shares. However, PBH has outperformed the market in the last 3 month and 2 week periods, returning +1.2% and +2.2%, while SPY returned -5.3% and -3.2%, respectively. This indicates PBH has been having a stronger performance recently.
PBH support price is $47.13 and resistance is $49.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBH shares will trade within this expected range on the day.